Floatz logo

Therapeutic Asset Ratings

407 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Cetuximab
Lung Cancer
Merck Sharp & Dohme LLCP3B (62)
Cyclophosphamide
Cervical Cancer
Merck Sharp & Dohme LLCP3B (62)
DEXAMETHASONE
Cancer
Merck Sharp & Dohme LLCP3B (62)
DEXAMETHASONE
Prostatic Neoplasms
Merck Sharp & Dohme LLCP3B (62)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Bladder Cancer
Merck Sharp & Dohme LLCP3B (62)
Epirubicin
Cervical Cancer
Merck Sharp & Dohme LLCP3B (62)
Olaparib
Breast Neoplasms
Merck Sharp & Dohme LLCP3B (62)
Pembrolizumab
Cervical Cancer
Merck Sharp & Dohme LLCP3B (62)
Docetaxel
Cholangiocarcinoma
Merck Sharp & Dohme LLCP2B (62)
Epirubicin
Cutaneous Squamous Cell Carcinoma
Merck Sharp & Dohme LLCP2B (62)
Pembrolizumab
Cutaneous Squamous Cell Carcinoma
Merck Sharp & Dohme LLCP2B (62)
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
B-All
Merck Sharp & Dohme LLCP2/3B (62)
Benadryl
B-Cell Leukemia
Merck Sharp & Dohme LLCP2/3B (62)
FENTANYL
B-All
Merck Sharp & Dohme LLCP2/3B (62)
Ketorolac Tromethamine
B-All
Merck Sharp & Dohme LLCP2/3B (62)
TAMOXIFEN
Chemotherapy
Merck Sharp & Dohme LLCP2/3B (62)
Benadryl
Prostate Cancer
Merck Sharp & Dohme LLCP4B (61)
Cyclophosphamide
Prostatic Neoplasms
Merck Sharp & Dohme LLCP3B (61)
Docetaxel
Lung Neoplasms
Merck Sharp & Dohme LLCP3B (61)
Epirubicin
Prostatic Neoplasms
Merck Sharp & Dohme LLCP3B (61)
Procarbazine
Classical Hodgkin Lymphoma
Merck Sharp & Dohme LLCP3B (61)
Carboplatin
Stomach Neoplasms
Merck Sharp & Dohme LLCP2B (61)
LENVATINIB
Cutaneous Squamous Cell Carcinoma
Merck Sharp & Dohme LLCP2B (61)
Enzalutamide
Metastasis
Merck Sharp & Dohme LLCP2/3B (61)
Epirubicin
Merkel Cell Carcinoma
Merck Sharp & Dohme LLCP2/3B (61)
Showing 76 to 100 of 407 assets
PreviousPage 4 of 17Next